Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pacher

Showing results (31-40 of 1,015) with videos related to

Pageof 102
Sort By:
American Heart Journal|April 16, 1998
Atrial natriuretic peptide release is more dependent on atrial filling volume than on filling pressure in chronic congestive heart failureS Globits, H Frank, B Pacher, et al.
British Journal of Pharmacology|May 23, 2012
Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversiesSabine Steffens, Pál Pacher
Orvosi Hetilap|April 6, 2004
[Cardiovascular effects of selective serotonin reuptake inhibitor antidepressants]Pál Pacher, Valéria Kecskeméti
Japanese Heart Journal|January 1, 1997
Dose-effect relationships of prostaglandin E1 in severe endstage chronic heart failureB Stanek, R Pacher
Pharmacological Research|July 2, 2009
Endocannabinoids and cardiac contractile function: pathophysiological implicationsSándor Bátkai, Pál Pacher
Current Opinion in Pharmacology|February 18, 2006
Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetesPál Pacher, Csaba Szabó
Current Medicinal Chemistry|April 14, 2004
Trends in the development of new antidepressants. Is there a light at the end of the tunnel?Pal Pacher, Valeria Kecskemeti
Wiener Klinische Wochenschrift|December 31, 2002
[Why heart failure clinics?]Martin Hülsmann, Richard Pacher
Current Pharmaceutical Design|August 24, 2004
Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?Pal Pacher, Valeria Kecskemeti
The FEBS Journal|April 5, 2013
Modulating the endocannabinoid system in human health and disease--successes and failuresPál Pacher, George Kunos
Pageof 102

Showing results (31-40 of 1,015) with videos related to

Sort By:
Pageof 102
American Heart Journal|April 16, 1998
Atrial natriuretic peptide release is more dependent on atrial filling volume than on filling pressure in chronic congestive heart failureS Globits, H Frank, B Pacher, et al.
British Journal of Pharmacology|May 23, 2012
Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversiesSabine Steffens, Pál Pacher
Orvosi Hetilap|April 6, 2004
[Cardiovascular effects of selective serotonin reuptake inhibitor antidepressants]Pál Pacher, Valéria Kecskeméti
Japanese Heart Journal|January 1, 1997
Dose-effect relationships of prostaglandin E1 in severe endstage chronic heart failureB Stanek, R Pacher
Pharmacological Research|July 2, 2009
Endocannabinoids and cardiac contractile function: pathophysiological implicationsSándor Bátkai, Pál Pacher
Current Opinion in Pharmacology|February 18, 2006
Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetesPál Pacher, Csaba Szabó
Current Medicinal Chemistry|April 14, 2004
Trends in the development of new antidepressants. Is there a light at the end of the tunnel?Pal Pacher, Valeria Kecskemeti
Wiener Klinische Wochenschrift|December 31, 2002
[Why heart failure clinics?]Martin Hülsmann, Richard Pacher
Current Pharmaceutical Design|August 24, 2004
Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?Pal Pacher, Valeria Kecskemeti
The FEBS Journal|April 5, 2013
Modulating the endocannabinoid system in human health and disease--successes and failuresPál Pacher, George Kunos
Pageof 102